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Abstract
Background—The wide variety of dissemination and implementation designs now being used to 
evaluate and improve health systems and outcomes warrants review of the scope, features, and 
limitations of these designs.
Methods—This paper is one product of a design workgroup formed in 2013 by the National 
Institutes of Health to address dissemination and implementation research, and whose members 
represented diverse methodologic backgrounds, content focus areas, and health sectors. These 
experts integrated their collective knowledge on dissemination and implementation designs with 
searches of published evaluations strategies.
Results—This paper emphasizes randomized and non-randomized designs for the traditional 
translational research continuum or pipeline, which builds on existing efficacy and effectiveness 
trials to examine how one or more evidence-based clinical/prevention interventions are adopted, 
scaled up, and sustained in community or service delivery systems. We also mention other designs, 
including hybrid designs that combine effectiveness and implementation research, quality 
improvement designs for local knowledge, and designs that use simulation modeling.
Keywords
implementation trial; scale up; adoption; adaptation; fidelity; sustainment
Introduction
Medicine and public health have made great progress through rigorous randomized clinical 
trials in determining whether an intervention is efficacious. The standards set by Fisher (39), 
who laid the foundation for experimental design first in agriculture, and by Hill (58), who 
developed the randomized clinical trial for medicine, provided a unified approach to 
examining the efficacy of an individual-level intervention versus control condition or 
comparative effectiveness of one active intervention against another. Practical modifications 
of the individual-level randomized clinical trial have been made to test for program or 
intervention effectiveness under realistic conditions in randomized field trials (40), as well as 
for interventions delivered at the group level (77), multilevel interventions (14, 15), complex 
(34, 70) or multiple component interventions (31), and tailoring or adapting the intervention 
to subject’s response to targeted outcomes (31, 74) or to different social, physical, or virtual 
environments (13). There is now a large family of designs for testing efficacy or 
effectiveness that randomize across persons, place, and time (or combinations of these) (15), 
as well as designs that do not use randomization, such as pre-post comparisons, regression 
discontinuity (106), time series and multiple baseline comparisons (5). While many of these 
designs rely on quantitative analysis, qualitative methods can also be used by themselves or 
in mixed-methods designs that combine qualitative and quantitative methods, to precede, 
confirm, complement or extend quantitative evaluation of effectiveness (83). Within this 
growing family of randomized, nonrandomized, and mixed method designs, reasonable 
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consensus has grown across diverse fields about when certain designs should be used and 
what sample size requirements and design protocols are necessary to maximize internal 
validity (42, 87).
Dissemination and implementation research represents a distinct stage, and the designs for 
this newer field of research are currently less well-established than those for efficacy and 
effectivness. Understanding the full range of these designs has impeded the development of 
dissemination and implementation science and practice. Dissemination and implementation 
ultimately aim to improve the adoption, appropriate adaptation, delivery, and sustainment of 
effective interventions by providers, clinics, organizations, communities, and systems of 
care. In public health, dissemination and implementation research is intimately connected to 
understanding how the following seven intervention categories can be delivered in and 
function effectively in different contexts: Programs (e.g. cognitive behavioral therapy), 
Practices (e.g., “catch-em being good” (84, 96), Principles (e.g., prevention before 
treatment), Procedures (e.g., screen for depression), Products (e.g., mHealth app for 
exercise), Pills (e.g., PrEP to prevent HIV infection) (51), and Policies (e.g., limit 
prescriptions for narcotics). This paper uses the term clinical/preventive intervention to refer 
to a single or multiple set of these 7 Ps that are intended to improve health for individuals, 
groups, or populations. Dissemination refers to the targeted distribution of information or 
materials to a specific public health or clinical audience while implementation involves “the 
use of strategies to adopt and integrate evidence-based health interventions and change 
practice patterns within specific settings” (49). Dissemination distributions and 
implementation strategies may be designed to prevent a disorder or the onset of an adverse 
health condition, may intercede around the time of this event, may be continuous over a 
period of time, or may occur afterwards.
Dissemination and implementation research pays explicit (although not exclusive) attention 
to external validity, in contrast to the main emphasis on internal validity in most randomized 
efficacy and effectiveness trials (20, 48, 52). Limitations in our understanding of 
dissemination and implementation have been well-documented (1, 2, 86). But some have 
called for a moratorium on randomized efficacy trials for evaluating new health interventions 
until we address the vast disparity between what we know could work under ideal conditions 
versus what we know about program delivery in practice and in community settings (63).
There is considerable debate as to whether and to what extent designs involving randomized 
assignment should be used in dissemination and implementation studies (79), as well as the 
relative contributions of qualitative, quantitative, and mixed methods (83). Some believe 
there is value in incorporating random assignment designs early in the implementation 
research process to control for exogenous factors across heterogeneous settings (14, 25, 66). 
Others are less sanguine about randomized designs in this context and suggest 
nonrandomized alternatives (71, 102). Debates about research designs for the emerging field 
of dissemination and implementation are often predicated on conflicting views of 
dissemination and implementation research and practice, such as whether the evaluation is 
intended to produce generalizable knowledge, support local quality improvement, or both 
(27), and the related underlying scientific issue of how much emphasis to place on internal 
validity compared to external validity (52).
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In this paper, we introduce a conceptual view of the traditional translational pipeline that 
was formulated as a continuum of research originally known as Levy’s arrow (68). This 
traditional translational pipeline is commonly used by the National Institutes of Health 
(NIH) and other research-focused organizations to move scientific knowledge from basic 
and other pre-intervention research, to efficacy and effectiveness trials, to a stage that 
reaches the public (66, 79). By no means does all of dissemination and implementation 
research follow this traditional translational pipeline, so we mention in the discussion 
section three different classes of research designs that are of major importance to 
dissemination and implementation research. We also mention other methodologic issues, as 
well as community perspectives and partnerships that must be taken into consideration.
This paper is a product of a design workgroup formed in 2013 by NIH in order to address 
dissemination and implementation research. We established a shared definition of terms that 
are often used differently across health fields. This required significant compromise, as the 
same words often have different meanings in different fields. Indeed, the term “design,” as 
used by quantitative or qualitative methodologists and intervention developers, is entirely 
different. Three terms we use repeatedly are process, output, and outcome. As used here, 
process refers to activities undertaken by the health system (e.g., frequency of supervision), 
output refers to observable measures of service delivery provided to the target population, 
(e.g., the numbers of the eligible population who take medication), and outcome refers only 
to health, illness, or health-related behaviors of individuals who are the ultimate target of the 
clinical/preventive intervention. We provide other consensus definitions involving 
dissemination and implementation and statistical design terms throughout the paper.
Where Dissemination and Implementation Fit in the Traditional Translational Pipeline
An updated version of the National Academy of Medicine (NAM; formerly the Institute of 
Medicine [IOM]) 2009 perspective on the traditional translational pipeline appears in Figure 
1. This top-down translation approach (79) begins with basic and other pre-intervention 
research at the lower left that can inform the development of novel clinical/preventive 
interventions. These new interventions are then tested in tightly controlled efficacy trials to 
assess impact under ideal conditions. Typically, a highly-trained research team would deliver 
this program to a homogeneous group of subjects with careful monitoring and supervision to 
ensure high fidelity. Recognizing that efficacy trials can answer only questions of whether a 
clinical/preventive intervention could work under rigorous conditions, such a program or 
practice that demonstrates sufficient efficacy would then be followed, in this traditional 
research pipeline, by an effectiveness trial in the middle of Figure 1, embedded in the 
community and/or organizational system where such a clinical/preventive intervention 
would ultimately be delivered. Such effectiveness trials typically have clinicians, other 
practitioners, or trained individuals from the community deliver the clinical/preventive 
intervention with ongoing supervision supported by researchers. Also, a more heterogeneous 
group of study participants are generally included in an effectiveness trial compared to an 
efficacy trial. These less-controlled conditions allow an effectiveness trial to determine if a 
clinical/preventive intervention does work in a realistic context.
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The final stage of research in this traditional translational pipeline model concerns how to 
make such a program work within community and/or service settings, the domain of 
dissemination and implementation research and the last stage of research in the traditional 
research pipeline. Following this pipeline, a prerequisite for conducting an implementation 
study would be that the clinical/preventive intervention has already demonstrated 
effectiveness. Effectiveness of the clinical/preventive intervention in this traditional research 
pipeline would be considered “settled law” so that proponents of this translational pipeline 
consider it unnecessary to re-examine effectiveness in the midst of an implementation 
research design (38, 100, 109). Thus, the traditional translational pipeline model is built 
around those clinical/preventive interventions that have succeeded in making it through the 
effectiveness stage.
We now describe the focus of dissemination and implementation research under this 
traditional research pipeline (see Figure 1 upper right). A tacit assumption of this pipeline is 
that wide-scale use of evidence-based clinical/preventive interventions generally requires a 
targeted information dissemination and often a concerted, deliberate strategy for 
implementation to move to this end of the diffusion, dissemination, and implementation 
continuum (53, 81, 94). A second assumption is that for a clinical/preventive intervention to 
have population-level impact, it must not only be an effective program, it must reach a large 
portion of the population, be delivered with fidelity, and maintained (50). Within the 
dissemination and implementation research agenda, there are phases of the implementation 
process itself that have been distinguished. A common exemplar, the “EPIS” conceptual 
model of the implementation process (1), identifies four phases as represented by the four 
white boxes within implementation illustrated in Figure 1. The first of these phases, 
Exploration, refers to whether a service delivery system (e.g., health care, social service, 
education) or community organization would find a particular clinical/preventive 
intervention useful for them given their outer context (e.g., service system, federal policy, 
funding) and inner context (e.g., organizational climate, provider experience). The 
Preparation phase refers to putting into place the collaborations, policies, funding, supports, 
and processes needed across the multilevel outer and inner contexts to introduce this new 
clinical/preventive intervention into this service setting once the adoption decision is made. 
In this phase, adaptations to the service system, service delivery organizations, and the 
clinical/preventive intervention itself are considered and prepared. The Implementation (with 
fidelity) phase refers to the support processes that are developed both within a host delivery 
system and its affiliates to recruit, train, monitor, and supervise intervention agents to deliver 
the intervention with adherence and competence and if necessary to adapt systematically to 
the local context (35). The final phase is Sustainment, referring to how a host delivery 
system and organizations maintains or extends the supports as well as the clinical/preventive 
intervention, especially after initial funding has ended. The entire set of structural, 
organizational, and procedural processes that form the support structure for a clinical/
preventive intervention is referred to in this paper as the implementation strategy; this is 
viewed as distinct from, but generally dependent on, the specific clinical/preventive 
intervention that is being adopted.
Also shown in this diagram is a contrast between local formative evaluation or quality 
improvement, and generalizable knowledge, represented by the depth dimension of the 
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dissemination and implementation box. Local evaluation is generally designed to test and 
improve the performance of the implementation strategy to deliver the clinical/preventive 
intervention in that particular setting, with little or limited interest in generalizing their 
findings to other settings. Implementation studies designed to produce generalizable 
knowledge contrast in obvious ways with this local evaluation perspective, but systematic 
approaches to adaptation can provide generalizable knowledge as well. In the traditional 
translation pipeline, most of the emphasis is on producing generalizable knowledge.
This traditional pipeline does not imply that research always continues to move in one 
direction as the sequential progression of intervention studies is often cyclical (14). Trial 
designs may change as well through this pipeline. Efficacy or effectiveness trials nearly 
always use random assignment, while implementation research often requires tradeoffs 
between a randomized trial design that can have high internal validity but is difficult to 
mount, and an observational intervention study that has little experimental control but still 
may provide valuable information (71).
Designs for Dissemination and Implementation Strategies
This section examines three broad categories of designs providing within-site, between-site, 
and within and between-site comparisons of implementation strategies.
Within-Site Designs
Post Design of an Implementation Strategy to Adopt an Evidence-Based 
Clinical/Preventive Intervention in a New Setting—The simplest—and often most 
common design, is a post design, which examines health care processes and health care 
utilization or output after introduction of an implementation strategy focused on the delivery 
of an evidence-based clinical/preventive intervention in a novel health setting. The emphasis 
here is on changing health care process and utilization or output rather than health outcomes 
(i.e., not measures of patient or subject health or illness). As an example, consider the 
introduction of rapid oral HIV testing in a hospital-based dental clinic, potentially useful 
based on the sensitivity and specificity of this test. The Centers for Disease Control and 
Prevention (CDC) has recently proposed that dental clinics could deliver this new 
technology, and there are real questions about whether such a strategy would be successful. 
Implementation requires partnering with the dental clinic (Exploration phase), which would 
need to accept this new mission, and hiring of a full-time HIV counselor to discuss results 
with patients (Preparation). Here, a key process measure is the rate in which HIV testing is 
offered to appropriate patients. Two key output measures are the rate at which an HIV test is 
conducted and the rate of new HIV positives. Blackstock and colleagues’ study (8) was 
successful in getting dental patients to agree to be tested for HIV within the clinic, but it had 
no comparison group and did not collect pretest rates of HIV testing among all patients. This 
program did identify some patients who had not previously been tested and were found to be 
HIV positive.
For implementation of a complex clinical/preventive intervention in a new setting, this post 
design can be useful in assessing factors predicting program adoption. For example, all of 
California’s county-level child welfare systems were invited to be trained to adopt 
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Multidimensional Treatment Foster Care, an evidence-based alternative to group care (23). 
Only a post test was needed to assess adoption and utilization of this program because the 
sole purveyor of this program clearly knew when and where this program was being used in 
any California communities (25). Post designs are also useful when new health guidelines or 
policy changes occur.
Pre-Post Design of an Implementation Strategy of a Clinical/Preventive 
Intervention already in Use—Pre-post studies require information about pre-
implementation levels. Some clinical/preventive interventions are already being used in 
organizations and communities, but do not have the reach into the target population that 
program objectives require. A pre-post design can assess such changes in reach. In a pre-
post implementation design, all sites receive a new implementation strategy for a clinical/
preventive intervention that is already being used, with measurement of process or output 
prior to implementation and after this strategy begins. Effects due to the new implementation 
strategy are inferred from these pre to post within-site changes. One example of a study 
using this design is the Veterans Administration’s use of the Chronic Care Model for 
inpatient smoking cessation (61). A primary output measure in this study is the number of 
prescriptions for smoking cessation. This pre-post design is useful in examining the impact 
of a complex implementation strategy within a single organization or across multiple sites 
that are representative of a population (e.g., federally qualified health centers).
Pre-post designs are also useful in assessing the adoption by health care systems of a 
guideline, black box warning, or other directive. For example, the comparison of 
management strategies used for inpatient cellulitis and cutaneous abscess were compared for 
all patients with these discharge diagnoses in the year prior to and after guidelines were 
published (8). The effects on prescribing antidepressants to depressed youth due to a black 
box warning was evaluated by comparing prescription rates (46) and adverse event reports 
(47) prior to and after the warning.
A variant of the pre-post design involves a multiple baseline time-series design. Biglan and 
colleagues examined the prevalence of tobacco sales across time to young people without 
checking birthdays after an outlet store reward and reminder system was implemented (7).
Between-Site Designs
In contrast to previous designs that examined changes over time within one or more sites 
exposed to the same dissemination or implementation strategy, these designs compare 
processes and output among sites having different exposures.
New Implementation Strategy Versus Usual Practice Implementation Designs
—In new versus Implementation As Usual (IAU) designs, some sites receive an innovative 
implementation strategy while others maintain their usual condition. Process and output 
measures can then be compared between the two types of sites over the same period of time. 
It is possible to use such a design even when one site introduces a new dissemination or 
implementation approach. As a policy dissemination example, Hahn and colleagues 
compared county-level smoking rates before and after the enactment of a smoke-free law in 
one county, comparing this county’s response to 30 comparison counties with similar 
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demographics (54). The effects of the law are evaluated using a regression displacement 
design (111) that uses multiple time points to examine changes in trajectories for those 
receiving this policy intervention compared to those that do not.
One illustration where self-selection is important comes from an educational outreach 
strategy to affect prescribing practices of physicians in managing the bacterium Helicobacter 
pylori (55). Part of this study involved a randomization of practices; those assigned to the 
active intervention arm were to receive educational outreach and auditing. However, only 
one half of these practices accepted the educational outreach and only 8% permitted the 
audit, thus severely limiting the value of the randomized trial. It is still possible to compare 
prescribing differences among those practices that did receive educational outreach and 
those that did not, and this was the primary purpose of the paper (55). Interpretation of such 
differences in this now observational study may be challenging as there may be confounding 
by selection factors that distinguish those practices that were willing and those that were not 
willing to receive educational outreach. Principles of diffusion of innovation could help 
understand why some organizations adopt an implementation strategy while others do not 
(97). Propensity scores, based on site-level covariates, are useful in controlling for some 
degree of assignment bias (98, 104).
In a randomized New versus IAU trial, the goal is to determine whether the new 
implementation strategy produces better or more efficient process and outputs, (e.g., 
improved reach or penetration of the innovation, or improved utilization of a health care 
standard or innovation) compared to what now exists (41). Here the sites (practices, 
communities, organizations) are assigned randomly to the new active implementation or 
usual practice condition. As random assignment is at the group rather than individual level, 
this forms a cluster-randomized design (75, 95). Process and output measures used as the 
primary endpoints are measured for all eligible patients or subjects in both conditions and 
aggregated to the level of the randomized unit. Such a randomized implementation trial tests 
whether the new implementation strategy increases utilization of a health care innovation.
One example of a successful evaluation of an implementation strategy is the PROSPER 
study, which randomly assigned 28 communities to receive a supportive strategy for 
implementing a combination of evidence-based school and family preventive interventions 
for youth substance abuse, or to usual practice in the community. With this design, the 
investigators were able to evaluate initial adoption as well as sustainment and fidelity across 
multiple cohorts (103).
Instead of larger health organizational sites being randomized, smaller units can sometimes 
be randomized within each organization. Randomization could occur at the level of the 
ward, team, clinician, or even at the level of patients or subjects within each site, again 
assessing health care service utilization as the primary outcome. Such a design uses site as a 
blocking factor in contrast to the design described above. For example, if similar teams exist 
and work relatively independently within each organization, an efficient design is to 
randomly assign teams within each organization into blocks so that a precise comparison can 
be made between implementation strategies within each organization (12). With complex, 
multilevel implementation strategies involving the adoption of clinic-level practices, there is 
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a potential for contamination if two implementation conditions are tested in the same site. 
For example, if one were to test the introduction of system-level policies for practitioners to 
increase hand washing at the bedside, a design that randomized small subunits within the 
system would not be able to test a fully implemented systems approach. A useful rule of 
thumb is to randomize at the “level of implementation,” that is, at the level where the full 
impact of the strategy is designed to occur (12). In a recent experiment that tested a hand 
washing implementation strategy, there was feedback at ward-level meetings (43). Thus, a 
ward-level randomization was appropriate for this trial.
A few implementation strategies can be tested with randomization even down to the 
individual patient level. These are strategies where a) leakage of the implementation to other 
patients is likely to be minimal, and b) the implementation’s impact is not likely to be 
attenuated due to its exposure on only a portion of patients. An example is the use of 
automated systems to screen and/or refer patients. Minimal leakage is likely to occur with 
strategies that involve automated messages to patients, so individual-level randomized 
designs are appropriate. A recent review of system, practitioner, and individual patient-level 
randomized trials to evaluate level-specific lipid management approaches that all used a 
health information technology component concluded that systems and individual patient 
implementations showed better management (4).
One type of new versus usual practice randomized design for implementation is built around 
the theme of encouraging system-level health behavior through incentives for desired 
behavior or penalties for undesired behavior. In these randomized encouragement 
implementation designs, one strategy receives more attention or incentives than the other. 
The effect of providing incentives or supports for succeeding to implement or penalties for 
failing to implement can be evaluated with such a design. An example involves the pay for 
performance (P4P) strategy to increase therapist adherence to a protocol for adolescent 
substance abusers (45), as therapists receive financial compensation if they achieve a 
specified level of competence and have the adolescent complete treatment sessions.
Head-to-Head Randomized Implementation Trial Design—A head-to-head 
randomized implementation trial is a comparative effectiveness implementation trial that 
tests which of two active, qualitatively different implementation strategies is more successful 
in implementing a clinical/preventive intervention. Here the same clinical/preventive 
intervention is used for both arms of this trial, and health or service system units are 
assigned randomly to one of the two different implementation strategies as shown in Figure 
2. Both implementation strategies are manualized and carried out with equivalent attention 
to fidelity. The two implementation strategies are compared on the quality, quantity, or speed 
of implementing the clinical/preventive intervention (11).
An example of the use of such a head-to-head randomized implementation trial is the CAL-
OH trial that compares two alternative strategies of a county-level implementation of 
Multidimensional Treatment Foster Care (MTFC) (23, 26), an evidence-based program for 
foster children and their families that is conducted in the child welfare, juvenile justice, and 
mental health public service systems in California and Ohio. A total of 51 counties were 
randomized to one of two implementation conditions: an individual county implementation 
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strategy (IND), or a community development team (CDT) involving multiple counties in a 
learning collaborative (11). A diagram of the design of this trial is shown in Figure 3. 
Counties were assigned randomly to a cohort, which governed when they would start the 
implementation process, as well as to an implementation strategy condition. This type of 
roll-out design, where counties’ start times were staggered, was chosen because it balanced 
the demand for training the counties with the supply of training resources available by the 
purveyor. Counties were matched across a wide range of baseline characteristics so that 
cohorts formed equivalent blocks. A Stages of Implementation Completion (SIC) measure 
(24) was developed and used to evaluate the implementation process including the quality of 
preparedness and training to deliver MTFC, the speed that milestones were achieved, and the 
quantity of eligible families served (11). Head-to-head testing involved analyzing how 
combinations of the SIC items’ distributions varied by implementation condition (11).
Another type of head-to-head trial design involves two implementation strategies that target 
different outcomes, with no site receiving both. This design allows each site to serve as both 
an active intervention and a control because the two implementation targets focus on 
different patient populations. An example is the simultaneous testing of two clinical pathway 
strategies in emergency departments for pediatric asthma and pediatric gastroenteritis (59). 
Sixteen emergency departments are to be randomly assigned to one of these strategies, and 
key clinical output measures are assessed for asthma and gastroenteritis.
Dosage trials, which assign units to varying intensities of an intervention, are common in 
efficacy and effectiveness studies, but they can also be used with varying implementation 
intensity. An example is a trial focused on in-service training and supervision of first-grade 
teachers in the Good Behavior Game (GBG) to manage classroom behavior. For this trial, 
first-grade students within schools were assigned randomly to classrooms, and classrooms/
teachers were assigned randomly to no training, a low intensity GBG training and 
supervision, or a more intensive level of supervision with a coach (88, 89).
Designs for a Suite of Evidence-Based Clinical/Preventive Interventions—Up 
to now, this typology focuses on a single evidence-based clinical/preventive intervention. 
This one-choice option does not allow communities or organizations to select programs that 
match their needs, values, and resources. A decision support system to select evidence-based 
programs is, in fact, an implementation strategy, and such a support system can also be 
tested for impact using a well-crafted design.
An example of a randomized implementation trial of such a decision support system for 
prevention of youth substance use and violence is the Community Youth Development Study 
(CYDS). This randomized trial of 24 communities (18, 76) tested the Communities that Care 
(CTC) (57) comprehensive community support system against community control condition, 
which only received information about their community’s risk and protective factor profile 
but no technological help in determining which programs would be successful. This program 
measured implementation process milestones and benchmarks and compared both outputs, 
including the number of evidence-based prevention programs adopted by these communities 
and drug use and violence outcomes at the community level (19, 56, 73, 82). This study 
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found that the CTC decision support system led to greater adoption of evidence-based 
programs and prevented youth substance use and violence.
Factorial Designs for Implementation—Factorial designs for implementation 
investigate the combination of two or more implementation strategies at a time. Each 
experimental factor has two or more levels (e.g., presence or absence; low, medium, high 
intensity). A 2×2 factorial implementation design assigns units randomly to one of the four 
conditions and provides estimates of each factor by itself and their interaction. An example 
of a 3×3 design is the evaluation of three alternative screening tools for alcohol abuse in 
emergency departments, used in combination with three types of advice by an alcohol health 
worker (minimal intervention, brief advice, brief advice plus counseling). Individual 
emergency departments are randomized to a single screening tool and level of advice (33).
With incomplete factorial designs, one or more arms of a complete factorial are excluded 
from the study. For example, in a design involving the presence or absence of two 
implementation strategies, it may be viewed as unethical to withhold both strategies; thus, 
units may be assigned to either implementation or both. Alternatively, it may be too complex 
or unmanageable to conduct both implementation strategies in the same unit, therefore 
excluding the combined strategy.
We can consider testing a large number of components that go into an implementation 
strategy using Multiphase Optimization Strategy Implementation Trials (MOST) (29, 32, 69, 
85, 91, 112). This approach recognizes that many choices can be made in an implementation 
strategy. For example, a comprehensive implementation strategy often requires components 
that involve system leadership, the clinic level, the clinician level, as well as key processes: 
planning, educating, financing, restructuring, managing quality, and/or policy (90). Many of 
these components are thought to be necessary for an implementation strategy to work 
properly. With diverse approaches in the ways that these implementation components can be 
specified (92) and connected (105), as well as variations in strength, there is an exponential 
explosion of possible implementation strategies that can be developed. Testing all 
combinations in a single design is not feasible, but MOST can be used to identify and test an 
optimized intervention. MOST has three phases. The first phase, preparation, involves 
selection and pilot testing components with a clear optimization criterion (e.g., most 
effective components subject to a maximum cost). In the second phase, optimization, a fully 
powered randomized experiment is conducted to assess the effectiveness of each 
intervention component. The number of distinct implementation strategies is minimized 
using a balanced, fractional factorial experiment. Fractional designs can make examination 
of multiple components feasible, even when cluster randomization is necessary (30, 32, 37). 
The set of components that best meets the optimization criterion is identified based on the 
trial’s results. In the third phase, evaluation, a standard randomized implementation trial is 
conducted comparing the optimized intervention against an appropriate comparison 
condition.
An example of a MOST implementation trial involved determining which of a set of three 
components improved the fidelity of teacher delivery of Healthwise (21, 22) for use in South 
Africa. The three components were school climate, teacher training, and teacher supervision. 
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These three components were tested in a factorial experiment, assigning 56 schools to one of 
eight experimental conditions (22).
The Sequential Multiple Assignment Randomized Implementation Trial (SMART) 
implementation design is a special case of the factorial experiment (32, 67, 78) involving 
multistage randomizations where the site-level implementation process can be modified if 
unsuccessful. Such an adaptive approach to enhancing implementation can make the best 
allocation of available resources (31) and change its approach if a strategy is failing. For 
example, the Replicating Effective Programs (REP) strategy was developed to promote 
proper implementation of evidence-based health care interventions in community settings 
(80), but one study found that fewer than half of the sites sustained use of evidence-based 
interventions (65). In a subsequent study, Kilbourne et al. (2014) are using SMART to 
examine an adaptive version of REP (64). Initially, 80 community-based outpatient clinics 
are provided with REP. Clinics that do not respond are randomized to receive additional 
support from an external facilitator only, or both an external and internal facilitator. Clinics 
that are randomized to receive an external facilitator only and are still unresponsive will be 
re-randomized to continue with only an external facilitator or to add an internal facilitator.
In SMART designs, the adaptation probability within each site does not vary. Cheung et al. 
(2015) propose a SMART design with adaptive randomization (SMART-AR) in which the 
randomization probabilities of the strategies are updated based on outcomes in other sites, so 
as to improve the expected outcome (28). Such adaptations are potentially infinite if the 
interventions are complex and the intended populations and settings highly varied.
Doubly Randomized, Two-Level Nested Designs for Testing Two Nested 
Implementation Factors—In a doubly randomized two-level nested or split-plot 
implementation design, there are two experimental implementation factors directed towards 
two distinct hierarchical levels—for example, the practitioner and organization. A doubly 
randomized nested design can test whether additive or synergistic effects exist across the two 
levels. An example of this design is a trial for smoking cessation implementation, testing 
whether direct patient reimbursement for medication and/or physician group training 
influence the use of these medications. Patients are nested within physicians, and all four 
combinations are tested (107).
Within- and Between-Site Comparison Designs
Within- and between-site comparisons can be made with crossover designs where sites begin 
in one implementation condition and move to another. We use the generic term of a roll-out 
randomized implementation trial to refer to the broad class of designs where the timing of 
the start of an implementation strategy is randomly assigned. In the simplest roll-out design, 
all units start in a usual practice setting, then they cross over at randomly determined time 
intervals, and all eventually receive a new implementation strategy. Thus, at each time 
interval there is a between-units comparison of those units that are assigned to the new 
implementation strategy and those that remain as a usual practice setting. In addition, a 
within-unit comparison can be made as units change from a usual practice setting to a new 
implementation strategy at some randomly assigned time.
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Figure 4(a) shows this simplest type of roll-out design where all units are identified at the 
beginning of the study; all begin in usual practice, designated by 0 in this figure, and are 
randomly assigned to a cohort, i.e. when they are to receive the implementation strategy 
(time 1, 2, 3, or 4), designated by X*. After this startup period, the implementation strategy 
continues across the remaining time periods for those units that have crossed over to the new 
implementation strategy. We have designated this by X. Measures are taken across all 
cohorts at all time periods. This type of roll-out design has been used for about two decades 
in effectiveness trials, where it is known as a dynamic wait-listed design (17) or a stepped-
wedge design (10). Communities and organizations often are willing to accept this type of 
roll-out design over a traditional design when there are obvious or perceived advantages in 
receiving the new implementation strategy, or when it is unethical to withhold a new 
implementation strategy throughout the study (17).
Other roll-out designs can be used for implementation (111). In Figure 4(b), all sites start in 
an IAU and then at a random time are assigned to start one of two new implementation 
strategies, labeled X* and Y* in Figure 4(b). They continue in this same condition until the 
end of the study. A design such as this is being used in an ongoing trial in the juvenile justice 
system conducted by the National Institute on Drug Abuse (NIDA) and colleagues (6). We 
call this a head-to-head roll-out trial to distinguish it from stepped-wedge designs discussed 
above.
In addition, other types of roll-out designs could be used, but to our knowledge have not yet 
been used in implementation. A pairwise enrollment roll-out design (111) differs from the 
two we previously discussed and is similar to the original design for a roll-out randomized 
effectiveness trial of an HIV community-based intervention. In their original design (62), a 
pair of communities were randomized to receive the intervention in the first or second year; 
assessments were made for both communities in the first year to evaluate impact. This 
pairwise randomization would be repeated in following years so that over time a true 
randomized trial with sufficient numbers of units could be conducted. This type of pairwise 
enrollment roll-out design shown in Figure 4(c) could also work for implementation trials, 
thereby eliminating the need to enumerate all sites at the beginning of the study.
Discussion
In this paper, we have provided an extensive but admittedly incomplete compendium of 
designs that are or could be used in dissemination and implementation research under the 
general classification of the traditional translational pipeline. These are suitable for many 
clinical/preventive interventions that are judged to have successfully transcended the scale of 
evidence through effectiveness. This pipeline is useful in implementing a predetermined 
clinical/preventive intervention, or ones from a suite of evidence-based programs. Thus, 
these clinical/preventive interventions should be standardized and stable, subject to limited 
adaptation rather than allowed to change drastically. We presented designs for this pipeline 
involving within-site comparisons alone, between-site comparisons, and within- and 
between-site comparisons with roll-out designs. A wide range of factorial designs can also 
be used to evaluate multiple implementation components. Many of the designs we described 
involved randomization, which can often strengthen inferences, but there are many situations 
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where randomization is not possible or required, nor even advisable. For example, there are 
times when the policies are disseminated or implemented by law (93) or other nonrandom 
process. Likewise, dissemination or implementation may involve one single community or 
organization, with a research focus on understanding the internal diffusion process (110) 
involving network connections inside this system (108).
There are many excellent dissemination and implementation designs that address issues 
beyond those relevant to the traditional translational pipeline, and our focus on pipeline 
designs should in no way be interpreted as reducing the importance of these other designs. 
We note three broad types not discussed: those where effectiveness of the clinical preventive 
intervention is to be evaluated alongside questions involving implementation, which include 
hybrid designs (36) and continuously evolving interventions (72), those designs that address 
quality improvement for local knowledge (27), and designs involving simulation or synthetic 
experiments in dissemination and implementation (44). These designs will be presented 
elsewhere.
We did not provide details on statistical power in this review, despite its obvious importance. 
A few general comments on power should be made. Dissemination and implementation 
research, because it often tests system-level strategies, generally requires multilevel data 
with sizeable numbers of group level (e.g., practices or organizations) as well as individuals, 
as the statistical power of such designs is most strongly influenced by the number units at 
the highest level (75, 77). Some general approaches to increasing statistical power include 
blocking and matching within the design itself and analytical adjustment with covariates at 
the unit of randomization to reduce imbalance. Triangulating the findings of quantitative 
analyses with qualitative data in mixed method designs is another approach to addressing 
limited statistical power (83).
Neither have we discussed statistical analyses or causal inference related to specific designs. 
Again, we point out a few issues. First, it is common in implementation trials for many of 
the units assigned to an implementation strategy to end up not adopting the intervention. In 
such cases, there are analytic ways to account for self-selection factors related to adoption. 
One analytical approach to accounting for incomplete adoption is to use Complier Average 
Causal Effect (commonly known as CACE) modeling (3, 9, 60). Secondly, a primary 
outcome for most of these designs can be constructed as a composite process and output 
score, using dimensions of speed, quality and quantity (11, 25, 101).
In terms of causality, nonrandomized designs generally provide less confidence that the 
numerical comparisons are due to the differences in implementation conditions. For 
example, the effects of examining a new implementation in a post-test only design can be 
confounded with changes in multiple policies and other external factors, whereas a 
randomized new versus IAU maintains some protection. Such designs cannot completely 
rule out all unmeasured external effects the way randomized trials can. There are also some 
subtle issues that arise from group-randomized implementation trials (16). First is a 
conceptual problem of what is meant by causality at a group level. The standard assumptions 
put forward in some causal inference paradigms involving experimental trials are generally 
not valid for dissemination and implementation designs. Specifically, the assumption that a 
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subunit’s own output or outcomes are not affected by any other unit’s implementation 
assignment (what is called SUTVA (99)) is invalid, as interactions and synergistic effects 
underlie many of our implementation strategies. In addition, implementation strategies are 
inherently systemic rather than linear, and to date there is no fully-developed causal 
inference approach comparable to that of single-person randomized trials that addresses this 
cyclic nature of implementation. Despite these theoretical concerns, randomized 
dissemination and implementation trials can provide valuable information for policy and 
practice, as well as generalizable knowledge.
While we have provided some illustrations of the use of many of the designs discussed 
above, this paper does not provide recommendations regarding the appropriateness of one 
design over another. The choice of design is a complex process, with major input regarding 
the research questions; the state of existing knowledge; the intention to obtain generalizable 
or local knowledge; the community, organizational, and funder values, expectations, and 
resources; and the available opportunities to conduct such research (71). All of these factors 
are beyond the scope of this paper. Nevertheless, the designs listed here can be considered as 
options for researchers, funders, and organizational and community partners alike.
We close by reinforcing the message that researchers and evaluators represent only one 
sector of people that make design decisions in implementation. More than efficacy and 
effectiveness studies, dissemination and implementation studies involve major changes in 
organizations and communities, and as such, community leaders, organizational leaders, and 
policy makers have far more at stake than the evaluators. The most attractive scientific 
design on paper will not happen without the endorsement and agreement of the communities 
and organizations where this takes place.
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Figure 1. Traditional Translational Pipeline
*These dissemination and implementation stages include systematic monitoring, evaluation, 
and adaptation as required.
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Figure 2. 
Focus of Research in a Head-to-Head Randomized implementation Trial with Identical 
Clinical/Preventive Intervention and Different Implementation Strategies
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Figure 3. 
Randomize 40 Counties in CA to Independent County (IND) or Community Development 
Team (CDT) Implementation Strategy and Time (Cohort) Using a Randomized Roll-Out 
Design; 11 Counties in OH were Separately Randomized in a Fourth Cohort to the Same 
Implementation Strategies.
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Figure 4. Roll-Out Randomized Designs
Symbol “O” refers to implementation as usual, “X*” and “Y*” are introductions on new 
implementation strategies, and “X” and “Y” are continuation of these strategies over 
extended periods of time.
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